Predictive Oncology (NASDAQ:POAI) Stock Crosses Below 200 Day Moving Average – Here’s What Happened

Predictive Oncology Inc. (NASDAQ:POAI) shares crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $8.80 and traded as low as $2.39. Predictive Oncology shares last traded at $2.39, with a volume of 17,255 shares trading hands.

Wall Street Analyst Weigh In

Separately, Wall Street Zen downgraded Predictive Oncology to a “strong sell” rating in a report on Saturday, December 6th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Predictive Oncology Trading Down 5.4%

The firm has a market cap of $7.67 million, a price-to-earnings ratio of -0.17 and a beta of 1.35. The firm’s 50 day simple moving average is $5.07 and its two-hundred day simple moving average is $8.78.

About Predictive Oncology

Predictive Oncology, Inc is a biotechnology company that leverages artificial intelligence and digital biology to support drug discovery and development in oncology. Its core business revolves around the application of machine learning algorithms to high-content cellular imaging, multi-omic profiling, and clinical response data. By integrating these diverse data streams, the company aims to generate predictive models that forecast the efficacy and toxicity of candidate therapeutics, thereby accelerating preclinical decision-making and reducing development timelines.

The company’s primary offerings include its Phenomics platform, which combines automated microscopy with advanced image analysis to capture subtle phenotypic changes in cancer cells.